TTUHSC School of Pharmacy

Office of Sciences

Office of Sciences Banner


The Mission of the Office of Sciences at the TTUHSC School of Pharmacy is to coordinate the school's research needs with our state-of-the-art scientific and technical support and to promote and accelerate research grant applications and new award set-up. 

Office of Sciences
TTUHSC School of Pharmacy
1406 S. Coulter St.
Amarillo, Texas 79106


Faculty Contacts  

Online Directory

About Us

The Office of Sciences is available to all faculty on each of the four TTUHSC School of Pharmacy campus sites: Amarillo, Abilene, Dallas/Fort Worth and Lubbock. Our purpose is to act as a resource for the granting process, facilitate research and administer internal research programs.

Programs and Services

The Office of Sciences provides and oversees the following programs and services:

Faculty Honors & Achievements

 Featured Grants - 2017

  • Dr. Al-Ahmad Dr. Abraham Al-Ahmad has been accepted for participation in the Early Career Reviewer (ECR) Program at the Center forScientific Review (CSR), National Institutes of Health 
  • Dr. Mikelis Dr. Constantinos Mikelis was invited for a talk at the 14th Annual International Innate Immunity Conference on June 19-24, 2017 at Heraklion, Crete.

  • Dr.TrippierDr. Trippier was invited to present a seminar in the Early Career Investigators in Biological Chemistry Session at the American Chemical Society National Meeting on August 20-24, 2017. 
  • SrivastavaDr. Sanjay Srivastava delivered a Plenary Talk and was the Session Chair at the First International Conference on Clinical Trials and Innovative Therapeutics, July 24-26, 2017 in Cape Town, South Africa.

  • Hiranmoy DasDr. Hiranmoy Das was invited to talk at the 1st International Conference on Clinical Trials and Innovative Therapies at Cape Town, South Africa on July 24-26, 2017.  He was also invited to serve on several NIH study section meetings in 2017. 

 Dr. Cucullo  Dr. Abbruscato

Dr. Luca Cucullo and Dr. Thomas Abbruscato have received a Multi-PI NIH R01 Grant in the amount of $1.9 million. 

Dr. Leff

Dr. Richard Leff received a $2.5 million grant from CPRIT to fund the North Texas Pharmacology Cancer Core in Dallas, TX.

Dr. Kalkunte Srivenugopal

Dr. Kalkunte Srivenugopal received a $1.2 million CPRIT Grant.

Dr. Wood
Dr. Laurence Wood received a R15 grant from NIH. 

New Grants and Awards - 2017

Dr. Fakhrul Ahsan received CMREF grant

Dr. Abraham Al-Ahmad received  GLUT1 Deficiency Foundation grant

Dr. Magdalena Karbowniczek received a Women's Health Seed Grant from Laura W. Bush Institute for Women's Health

Dr. Maciej Markiewski receceived a Women's Health Seed Grant from Laura W. Bush Institute for Women's Health



Upcoming Event For School of Pharmacy

Research Days Save-the-Date

High Impact Publications

Cancer Research Cover

Dr. Sanjay K. Srivastava, Professor of Biomedical Sciences and Associate Dean for Office of Sciences, and his team's recent publication, "Penfloridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis."  Cancer Research, 76, 877-890, 2016. (Impact Factor  9.329) PMID: 26627008

Metastasis of breast cancer, especially to the brain, is the major cause of mortality. The inability of anticancer agents to cross the blood-brain-barrier represents a critical challenge for successful treatment.  In the current study, Dr. Srivastava and his team investigated the antimetastatic potential of penfluridol, an antipsychotic drug frequently prescribed for schizophrenia with anticancer activity. His group demonstrated that penfluridol induced apoptosis and reduced the survival of several metastatic triple-negative breast cancer (TNBC) cell lines and suppressed tumor growth in various models.

Can also be found at:

Media Coverage:



Dr. Magdalena Karbowniczek, Associate Professor in the Department of Immunotheapeutics and Biotechnology in Abilene, and her team’s recent publication, “Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex." Dr. Karbowniczek’s laboratory studies the cellular and molecular mechanisms behind a rare disease tuberous sclerosis complex (TSC), which is caused by the inactivating mutations in tumor suppressor genes TSC1 and TSC2. The manuscript is scheduled for publication this year in the cancer journal Oncogene. (Impact Factor 8.459)... READ ARTICLE

Can also be found in BioQuick News


Download Free Adobe Reader Get Adobe Reader   Adobe Acrobat Reader is required to view items marked with this icon: PDF Document Icon
Please click on the left image to download the free version.

Content updated on 11/20/17